CH CASTSON 81(00810) released its interim results, reporting a profit attributable to shareholders of HKD 4.198 million, turning from loss to profit year-on-year.
China Metal Resources Utilization 81 (00810) announced its interim results for the six months ended June 30, 2026, with total operating revenue of HK$41.338 million, a year-on-year increase of 1093.02%; profit attributable to shareholders of HK$4.198 million, reversing previous losses; and earnings per share of HK$0.0101.
CH CASTSON 81(00810) announced its interim results for the six months ended June 30, 2026, with total operating income of HK$41.338 million, representing a year-on-year increase of 1093.02%; net profit attributable to shareholders of HK$4.198 million, turning losses into profits year-on-year; earnings per share of HK$0.0101.
Related Articles
IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.
Suzhou Novosense Microelectronics (02676) announced its interim results, with a net profit attributable to the parent company of approximately 67.5918 million yuan, marking a turnaround from a loss to profit compared to the same period last year.
TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).
IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.
Suzhou Novosense Microelectronics (02676) announced its interim results, with a net profit attributable to the parent company of approximately 67.5918 million yuan, marking a turnaround from a loss to profit compared to the same period last year.
TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).
RECOMMEND
